Full Text View
Tabular View
No Study Results Posted
Related Studies
Far Infrared Radiation Treatment for Diabetes
This study is ongoing, but not recruiting participants.
Study NCT00573456   Information provided by GAAD Medical Research Institute Inc.
First Received: December 12, 2007   Last Updated: August 14, 2009   History of Changes

December 12, 2007
August 14, 2009
May 2006
February 2009   (final data collection date for primary outcome measure)
The primary end point is to determine the therapeutic effects of far infrared radiation on all types of diabetes. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00573456 on ClinicalTrials.gov Archive Site
The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other types of diabetes complications including blindness, heart and blood vessel disease and kidney failure. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
 
Far Infrared Radiation Treatment for Diabetes
Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Diabetes

A study to determine the use of far infrared (FIR) radiation for treatment of diabetes.

Diabetes mellitus is a disease in which glucose is not sufficiently metabolized. This results in high glucose levels in blood and glucose in the urine. Cells can starve because glucose is not being metabolized.

Both types of diabetes can cause dangerous complications, including blindness, heart and blood vessel disease, and kidney failure. A decrease in circulation may eventually require the amputation of limbs.

We are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby improving the health of the patients.

Phase I
Interventional
Allocation:  Non-Randomized
Control:  Uncontrolled
Endpoint Classification:  Efficacy Study
Intervention Model:  Single Group Assignment
Masking:  Open Label
Primary Purpose:  Treatment
Diabetes Mellitus
Radiation: Far Infrared Radiation
Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
1
Intervention: Radiation: Far Infrared Radiation
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
2
April 2009
February 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Persons with type 1 or type 2 diabetes

Exclusion Criteria:

  • None
Both
 
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00573456
Dr. Kwasi Donyina/Founder & President, GAAD Medical Research Institute Inc.
GAAD-DM-CTP1
GAAD Medical Research Institute Inc.
 
Study Director: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
Study Chair: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP